Alam N H, Meier R, Schneider H, Sarker S A, Bardhan P K, Mahalanabis D, Fuchs G J, Gyr N
Clinical Sciences Division, ICDDR,B, Centre for Health and Population Research, Dhaka, Bangladesh.
J Pediatr Gastroenterol Nutr. 2000 Nov;31(5):503-7. doi: 10.1097/00005176-200011000-00010.
Partially hydrolyzed guar gum (Benefiber; Novartis Nutrition, Minneapolis, MN, U.S.A.) is fermented by colonic bacteria liberating short-chain fatty acids (SCFAs), which accelerate colonic absorption of salt and water. The purpose of this study was to evaluate the effect of Benefiber (BF)-supplemented World Health Organization Oral Rehydration Solution (WHO ORS) in the treatment of acute noncholera diarrhea in children.
A double-blind, randomized, controlled clinical trial was performed at ICDDR,B in 150 male children aged 4 to 18 months who had watery diarrhea of less than 48 hours' duration. After admission, children were assigned to receive either WHO ORS or BF-supplemented WHO ORS until recovery. Major outcome measures, such as duration of diarrhea and amount of stool output, were compared between the treatment groups.
Patients receiving BF-supplemented WHO ORS had significantly reduced duration of diarrhea compared with the control group (mean +/- SD, 74 +/- 37 vs. 90 +/- 50 hours, P = 0.03). Survival analysis for duration of diarrhea also showed a reduction the BF-supplemented WHO ORS-treated group (P = 0.025, log rank test). There was also less stool output daily from days 2 through 7 in the patients treated with BF-supplemented WHO ORS compared with that in the children treated with WHO ORS; the reduction was significant on day 7 only.
Benefiber added to standard WHO ORS substantially reduces the duration of diarrhea and modestly reduced stool output in acute noncholera diarrhea in young children, indicating its potential as a new antidiarrheal therapy for acute diarrhea in children.
部分水解瓜尔胶（Benefiber；美国明尼阿波利斯市诺华营养公司）可被结肠细菌发酵，释放短链脂肪酸（SCFAs），从而加速结肠对盐和水的吸收。本研究旨在评估添加Benefiber（BF）的世界卫生组织口服补液盐（WHO ORS）治疗儿童急性非霍乱性腹泻的效果。
在孟加拉腹泻病研究国际中心对150名年龄在4至18个月、腹泻持续时间少于48小时的男童进行了一项双盲、随机、对照临床试验。入院后，将儿童分为接受WHO ORS或添加BF的WHO ORS治疗，直至康复。比较治疗组之间的主要结局指标，如腹泻持续时间和粪便排出量。
与对照组相比，接受添加BF的WHO ORS治疗的患者腹泻持续时间显著缩短（平均值±标准差，74±37小时对90±50小时，P = 0.03）。腹泻持续时间的生存分析也显示添加BF的WHO ORS治疗组有所缩短（P = 0.025，对数秩检验）。与接受WHO ORS治疗的儿童相比，接受添加BF的WHO ORS治疗的患者在第2天至第7天的每日粪便排出量也更少；仅在第7天差异显著。
在标准WHO ORS中添加Benefiber可显著缩短幼儿急性非霍乱性腹泻的持续时间，并适度减少粪便排出量，表明其作为儿童急性腹泻新止泻疗法的潜力。
